Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Feb 8;20:30. doi: 10.1186/s12943-021-01326-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Major features of the aggressive colon cancer CTC clones selected after treatment. a Boxplot showing cytidine deaminase (CDA) relative expression in normal colon (n = 41) and colon adenocarcinoma (n = 286) samples using UALCAN (p-value = 1.45E-06). b RT-qPCR analysis of CDA gene expression in the nine CTC lines (mean values of triplicate experiments with standard deviation). c ELISA measurement of CDA protein level (ng/ml) in the conditioned medium from the nine CTC lines (mean values from triplicate experiments with standard deviation). Aldolase B (ALDOB) expression analysis (d) by RT-qPCR in the nine CTC lines [*significant upregulation in the CTC-MCC-41.5 [ABFG] cell lines compared with all the other CTC lines (p-value = 0.0134), and only with the CTC-MCC-41.5 [CDE] lines (p-value = 0.0466); **significantly upregulation compared with all the other CTC lines (p-value = 0.0017)], and e in tissue samples (normal colon, normal liver, primary colorectal tumor, liver metastases of colon cancer) (n = 5/tissue). f Representation of the cancer hallmarks of the CTC lines resistant to treatment: (i) Stemness and Plasticity: metastasis-competent potential, (ii) Drug resistance: different molecules and pathways involved in treatment resistance and drug detoxification, such as the CDA enzyme implicated in pyrimidine analogue metabolism (e.g. for 5-FU), (iii) Metabolism: xenobiotic metabolism linked to therapy resistance, energy metabolism linked to mitochondrial activity, and ALDOB activity that gave information also on the liver metastasis origin of the CTC41.5[ABFG] lines. Abbreviation: EMT, epithelial-mesenchymal transition